INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Verzoni Elena

Main Facility: Oncologia Medica Genitourinaria

Drug: MK-2870 + ENFORTUMAB VEDOTIN (EV) IN COMBINATION WITH PEMBROLIZUMAB

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

Each participant will participate in the study for approximately 3 years from the time the participant provides documented informed consent through the final protocol-specified contact. After a screening period of up to 28 days, each participant will be assigned to receive study intervention until discontinuation criteria are met. After the end of treatment each participant will be followed for overall survival. Participants who discontinue for reasons other than radiographic disease progression will have posttreatment follow-up imaging for disease status until any of the conditions for discontinuation of imaging are met. After the end of treatment, each participant will be followed for the occurrence of adverse events and spontaneously reported pregnancy. All participants will be followed for overall survival until death, withdrawal of consent, or the end of the study.

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe